Fresenius Ends Deal to Buy Akorn, Which Pledges a Fight

Fresenius Ends Deal to Buy Akorn, Which Pledges a Fight


Fresenius SE on Sunday said it is terminating its $4.3 billion agreement to buy generic-drug maker Akorn Inc., but Akorn said it intends to see the deal go through.



from Biotech News